bph patient News
-
NYMOX Announces New Marketing Submission for NYMOZARFEX for BPH
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that a new formal submission has been made by the Company in Europe for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH). The trademarked name for the product in the application is NYMOZARFEX (TM). The Marketing Authorization Application (MAA) was submitted to the ...
-
NYMOX Provides Current Update
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on business developments. The Company has corresponded with and has met with the FDA during the past few months. The agency has provided very helpful feedback to the Company. FDA has specified what additional information is required in resubmission of the NDA; and the Company is in the process of preparing the ...
-
NYMOX Appeals Deficiency Letter
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) reports that on January 4, 2023 the Company received a deficiency letter from The Nasdaq Stock Market (“Nasdaq”) stating that, because the Company’s common stock continues to trade at less than $1.00 per share, the Company has not regained compliance with the Rule 5550(a)(2) requiring a minimum bid ...
-
Interim results of the Expander-1 Clinical Study
Medeon Biodesign, Inc. (TPEx: 6499), a Taiwan publicly traded medical device company, is pleased to announce positive interim results of the EXPANDER-1 Clinical Study for its flagship product the XFLO™ Expander System, an innovative, minimally invasive Benign Prostatic Hyperplasia (BPH) treatment solution. XFLO offers a reversible and office-based treatment option for patients who are ...
-
ProUroCare Announces Agreement for the Development of Real-Time Imaging System
ProUroCare Medical, Inc. (OTC BB: PRRC.OB) has entered into a co-development agreement with Urologix ®, Inc. (NASDAQ:ULGX) and Rensselaer Polytechnic Institute to develop a real-time temperature imaging system, ProUroVision™, to be utilized with Urologix’ Cooled ThermoTherapy™ treatment of benign prostatic hyperplasia (BPH) as well as potential new indications. Cooled ...
-
Zenflow Announces $24 Million Financing Round; Appoints Susan Stimson as President
Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), today announced that it has closed a $24 million Series B financing round. The funding was led by Invus Opportunities and included participation from F-Prime Capital, Medical Technology Venture Partners, Golden Seeds, Astia ...
-
Data presented at the American Urology Association annual conference
Data includes preliminary results from 39 patients at 4 centers across 3 countries – the temporary implant demonstrated the procedure was safe and provided immediate and sustained symptom relief. Prodeon Medical, Inc., a medical device company developing a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) caused by enlarged and obstructive benign prostatic ...
-
Promising Clinical Study Results of the Zenflow Spring System Featured at the AUA 2021 Meeting
Study results from the Spring System from Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), were featured at the American Urological Association 2021 annual meeting. The Spring System was designed with the patient experience in mind and relies on a small springlike coil to ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you